Table 2 Abstracted data from included studies
From: Early economic evaluation of emerging health technologies: protocol of a systematic review
Values | Source | |
|---|---|---|
Decision context | ||
Who initiate the evaluation? | For example, policy decision makers, industryb, third-party payers, hospital managers/administrators, clinicians, patients or patient advocacy groups, not reported | [27] |
Who commissioned it? | For example, policy decision makers, industryb, third-party payers, hospital managers/administrators, clinicians, patients or patient advocacy groups, not reported | [27] |
What are the funding sources of the study? | For example, public, private, both, others, not reported | [27] |
Why is an evaluation needed right now? | Informing product development, informing policies, not reported | [27] |
Who conducted the study? | For example, academia, public, private, multiple sources, others, not reported | [27] |
Primary target audience according to the decision context | For example, policy decision makers, industryb, third-party payers, hospital managers/administrators, clinicians, patients or patient advocacy groups, not reported | [27] |
Defining the decision problem | ||
Decision problem | Open coding. Decision problems will be classified. For example, the primary reason for initiating the early evaluation could be product development, health policy | |
Disease or clinical problem | ICD-10 major categories (see listing in footnotes) | [30] |
Target population | For example, patients, at-risk individuals, general public, unclear | [29] |
Health technology | ||
Technology type | For example, pharmaceuticals, medical devices, diagnostic devices, other therapeutic technologies | [28] |
Technology stage | For example, basic, translational research, clinical researchc | [8] |
Methodological aspects of the EE | ||
Perspective | For example, societal, publicly funded health-care system, third-party payers (e.g., insurance companies), not reported | |
Type of evaluations | For example, CEA, CUA, CMA, CBA, others | |
Basis of the evaluation | For example, trial-based, model-based, prospective or retrospective analysis, others | [29] |
Time horizon | Numerical number, not reported | |
Adjusted for differential timing? | Numerical percentage, not reported | |
Likely effect of the new technology | ||
Quantification of the likely effecta | Open coding to identify data sources, methods, assumptionsd | |
Valuing health outcomes | ||
Valuation of the likely effecta | Open coding to identify data sources, methods, assumptionsd | |
Resources used and costs | ||
Quantification of the likely impact on resourcesa | Open coding to identify data sources, methods, assumptionsd | |
Modeling, if appropriate | ||
Model type | For example, decision tree, state transition (e.g., Markov), discrete event simulation, dynamic transition model, others | |
Handling of variability and uncertainty | ||
Scenario analysis (e.g., structural uncertainty) | Yes, no | |
Sensitivity analysis (e.g., one-way, multiple-way) | Yes, no | |
Probabilistic sensitivity analysis | Yes, no | |
Value-of-information analysis | Yes, no | |
Presenting results of the economic evaluation | ||
According to the authors, are results likely to be influential to the decision problem? | Yes, no, unclear | |
According to the reviewers, are results likely to be influential to the decision problem? | Yes, no, unclear |